Jaka jest cena za Arch Biopartners Inc. (ARCH)

Cena za Arch Biopartners Inc. (ARCH) wynosi $0.73393689

Jaka jest kapitalizacja rynkowa dla Arch Biopartners Inc. (ARCH)

Kapitalizacja rynkowa dla Arch Biopartners Inc. (ARCH) wynosi $49.86M

Arch Biopartners Inc. (ARCH) Marża Operacyjna

Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.

Rok	Marża operacyjna	Zmień
Za mało danych dla podanych dat.

Rok

Marża operacyjna

Zmień

Za mało danych dla podanych dat.

Firma	Marża operacyjna	Różnica w marży operacyjnej	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH
Moderna, Inc. MRNA.US	-149.01%	-	US

Firma

Marża operacyjna

Różnica w marży operacyjnej

Kraj